Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Ambient light activatable opsin based therapy for age-related macular degeneration

    SBC: NANOSCOPE TECHNOLOGIES LLC            Topic: NEI

    Severe loss of vision occurs due to age related macular degenerationAMDand approximatelymillion people in the US have some form of AMDwhich is expected to double byMost of the current clinical treatments are primarily focused on slowing down the progression of the diseaseas there is neither a cure that can stop the degeneration nor a therapyother than retinal prosthesesthat can restore vision lost ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Developing an automated yeast dissection system for aging research

    SBC: Innovative BioChips LLC            Topic: NIA

    PROJECT SUMMARY Developing an Automated Yeast Dissection System for Aging ResearchAging is the single greatest risk factor for diseases that are principal causes of mortalityThe objectives of aging research are to discover key genes and pathways related to aging that may eventually contribute to retardation of aging and a delay in the onset of age associated diseasesThe budding yeast Saccharomyces ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Novel therapeutic approach in treatment of glioblastoma using sustained delivery of Connxin43 carboxy-terminal peptide encapsulated in biodegradable nanoparticles in combination with temozolomide

    SBC: FirstString Research, Inc            Topic: 102

    PROJECT SUMMARY GlioblastomaGBMis an incurable cancer even with aggressive therapies such as surgical resection followed by radiotherapy and chemotherapy using temozolomideTMZEfforts to improve surgical resection or the efficacy of irradiation are limited by the potential damage these interventions cause to the brainIn contrastsensitizing GBM to TMZ is an appealing strategy because TMZ has excelle ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Development of TP-317 for the Induction and Maintenance of Remission in Ulcerative Colitis Patients

    SBC: Thetis Pharmaceuticals LLC            Topic: 300

    ABSTRACTThetis plans to investigate TPan innovative and potential first in class therapeutic agentas an oral therapy for the induction and maintenance of remission of intestinal inflammation symptoms in ulcerative colitisUCpatientsWhile the precise etiology of UC is unknownit is thought to result from an inappropriate inflammatory response to commensal gut bacteria in genetically susceptible indiv ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Fluorescent Diagnostic Agents for Detection, Staging, andIntraoperative Imaging of Tumors

    SBC: Onconano Medicine, Inc.            Topic: 102

    Abstract The goal of this project is to develop IV injectable fluorescent agents for use in intraoperative imaging of peritoneal metastatic tumorsSignificancePeritoneal metastatic cancers have an incidence ofper year in the US and are primarily treated with surgeryComplete surgical tumor resection is a gold standard treatment goal that can increase theyear patient survival towhereas incomplete tum ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Zinc(II) Sensitive MRI Contrast Agents as Diagnostic Sensors for Tracking Insulin Secretion

    SBC: VITALQUAN LIMITED LIABILITY COMPANY            Topic: NIDDK

    ABSTRACT SignificanceDiabetes mellitus typeT Dand particularly typeT Dandgtof casesare becoming an increasing burden on socioeconomic resources with vastly increasing patient numbers all over the worldInsulin dependent treatment regimen such as regular insulin injections are well established for both T D and T D but have been associated with a negative impact on the quality of life of patients wit ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Preclinical evaluation of a novel small molecule STAT inhibitor

    SBC: FANNIN PARTNERS, LLC            Topic: NIAID

    Project Summary Problem statementAsthma is one of the most common and burdensome of all chronic inflammatory diseasescausing almost lifelong respiratory symptoms to various degrees through a patient s life due to severe airway inflammationairway obstructionand triggered hyper responsivenessAlmostof these individuals experience very severecomplexand heterogeneous disease symptoms that remain intrac ...

    SBIR Phase II 2018 Department of Health and Human Services
  8. A Method to Increase Buprenorphine Treatment Capacity and Effectiveness

    SBC: CBT4CBT, LLC            Topic: R42

    The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioiddependent patientsOvermillion people in the US are addicted to opiatesProviding effective agonist therapymethadone or buprenorphinecoupled with behavioral counseling greatly improves outcomesreduces morbidityand reduces societal costsMethadone maintenance treatment has been limited due to complex sta ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a hybrid transcatheter mitral valve replacement and repair device

    SBC: Dura LLC            Topic: NHLBI

    PROJECT SUMMARYMitral regurgitationMRis the most prevalent valvular heart disease in the U Saffecting approximatelyof the populationThere aremillion patients in the US with moderate to severe MR requiring treatmentHoweveronly approximatelypatients in the U Sundergo surgery for MR each year due to concerns about procedural complexity and patient safetyThere is great enthusiasm among the heart valve ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Additional costs related to formulation, chronic tox and general development of PTI-125

    SBC: PAIN THERAPEUTICS, INC.            Topic: NIA

    Project Summary Abstract PTIis a novel small molecule AD therapeutic candidate with a novel target and mechanism of actionPTIbinds and reverses an altered conformation of the scaffolding protein filamin AFLNAto prevent Aandapos s tight binding to and toxic signaling via thenicotinic acetylcholine receptornAChRas well as Aandapos s aberrant activation of toll like receptorTLRHenceby restoring FLNAa ...

    SBIR Phase II 2018 Department of Health and Human Services
US Flag An Official Website of the United States Government